aluates Reports

$ 0.0

Automative

Global Vebreltinib Enteric Capsules Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-39K18021

Global Vebreltinib Enteric Capsules Market Research Report 2024

BUY CHAPTERS

Global Vebreltinib Enteric Capsules Market Research Report 2025

Code: QYRE-Auto-39K18021

Report

June 2025

Pages:67

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Avistone Pharmaceuticals Biotechnology

Asymchem

Vebreltinib Enteric Capsules Market Size

The global market for Vebreltinib Enteric Capsules was valued at US$ 41.0 million in the year 2024 and is projected to reach a revised size of US$ 139 million by 2031, growing at a CAGR of 19.0% during the forecast period.

Vebreltinib Enteric Capsules Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Vebreltinib Enteric Capsules competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Vebreltinib enteric capsules are an oral medication used in the treatment of cancers with specific MET gene alterations, particularly in cases of non-small cell lung cancer (NSCLC). Vebreltinib is a selective MET receptor tyrosine kinase inhibitor that targets and blocks the MET receptor, which is involved in tumor growth and metastasis.

Vebreltinib (brand name: Wanbirui®) is a highly selective c-Met inhibitor developed by Crown Bioscience Taicang, a subsidiary of Crown Bioscience Inc. On November 16, 2023, vebreltinib received conditional approval from the China National Medical Products Administration (NMPA) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. This approval marks a significant milestone for domestically developed precision oncology therapies targeting MET alterations.

At the 2023 ESMO Congress, results from the pivotal Phase II KUNPENG trial were presented, showing impressive efficacy in METex14-altered advanced NSCLC. The objective response rate (ORR) was 75.0%, with a median progression-free survival (mPFS) of 14.1 months and median overall survival (OS) of 20.7 months. These results position vebreltinib competitively against global MET inhibitors. The treatment demonstrated a favorable safety profile, with the most common treatment-related adverse events being peripheral edema (56.6%), hypoalbuminemia (22.1%), and hypoproteinemia (19.5%), mostly Grade 1 or 2 in severity. No significant irreversible or fatal toxicities were reported.

The enteric capsule formulation is designed to protect the active compound from degradation in the acidic stomach environment, thereby improving oral bioavailability and reducing gastric irritation. This formulation offers advantages in patient compliance and pharmacokinetic consistency, making it well-suited for long-term cancer therapy.

In the market landscape, vebreltinib competes with existing MET inhibitors such as Capmatinib (Novartis) and Tepotinib (Takeda), both of which are imported and priced at a premium. As a domestically developed product, vebreltinib is well-positioned for broader accessibility through national reimbursement negotiations and aligns with China's strategic goal of achieving self-sufficiency in high-end therapeutics. With the growing adoption of next-generation sequencing (NGS), MET mutations are increasingly identified, expanding the eligible patient population. Vebreltinib is also under investigation for additional indications including MET amplification, RET fusions, and gliomas, suggesting potential as a pan-cancer targeted therapy. Its strong clinical efficacy, manageable safety profile, optimized formulation, and domestic origin collectively indicate that vebreltinib is poised to secure a significant share in China's MET-targeted therapy market and potentially in global oncology as well.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Vebreltinib Enteric Capsules, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vebreltinib Enteric Capsules.

The Vebreltinib Enteric Capsules market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vebreltinib Enteric Capsules market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Vebreltinib Enteric Capsules manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Vebreltinib Enteric Capsules Market Report

Report Metric	Details
Report Name	Vebreltinib Enteric Capsules Market
Accounted market size in year	US$ 41.0 million
Forecasted market size in 2031	US$ 139 million
CAGR	19.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	25mg per Unit 100mg per Unit
Segment by Application	Glioma Non-small Cell Lung Cancer
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Avistone Pharmaceuticals Biotechnology, Asymchem
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vebreltinib Enteric Capsules manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vebreltinib Enteric Capsules in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Vebreltinib Enteric Capsules Market growing?

Ans: The Vebreltinib Enteric Capsules Market witnessing a CAGR of 19.0% during the forecast period 2025-2031.

What is the Vebreltinib Enteric Capsules Market size in 2031?

Ans: The Vebreltinib Enteric Capsules Market size in 2031 will be US$ 139 million.

Who are the main players in the Vebreltinib Enteric Capsules Market report?

Ans: The main players in the Vebreltinib Enteric Capsules Market are Avistone Pharmaceuticals Biotechnology, Asymchem

What are the Application segmentation covered in the Vebreltinib Enteric Capsules Market report?

Ans: The Applications covered in the Vebreltinib Enteric Capsules Market report are Glioma, Non-small Cell Lung Cancer

What are the Type segmentation covered in the Vebreltinib Enteric Capsules Market report?

Ans: The Types covered in the Vebreltinib Enteric Capsules Market report are 25mg per Unit, 100mg per Unit

Recommended Reports

Targeted Cancer Drugs

Cancer Capsule Therapies

Oncology Therapeutics Market

1 Vebreltinib Enteric Capsules Market Overview

1.1 Product Definition

1.2 Vebreltinib Enteric Capsules by Type

1.2.1 Global Vebreltinib Enteric Capsules Market Value Comparison by Type (2024 VS 2031)

1.2.2 25mg per Unit

1.2.3 100mg per Unit

1.3 Vebreltinib Enteric Capsules by Application

1.3.1 Global Vebreltinib Enteric Capsules Market Value by Application (2024 VS 2031)

1.3.2 Glioma

1.3.3 Non-small Cell Lung Cancer

1.4 Global Vebreltinib Enteric Capsules Market Size Estimates and Forecasts

1.4.1 Global Vebreltinib Enteric Capsules Revenue 2020-2031

1.4.2 Global Vebreltinib Enteric Capsules Sales 2020-2031

1.4.3 Global Vebreltinib Enteric Capsules Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Vebreltinib Enteric Capsules Market Competition by Manufacturers

2.1 Global Vebreltinib Enteric Capsules Sales Market Share by Manufacturers (2020-2025)

2.2 Global Vebreltinib Enteric Capsules Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Vebreltinib Enteric Capsules Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Vebreltinib Enteric Capsules, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Vebreltinib Enteric Capsules, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Vebreltinib Enteric Capsules, Product Type & Application

2.7 Global Key Manufacturers of Vebreltinib Enteric Capsules, Date of Enter into This Industry

2.8 Global Vebreltinib Enteric Capsules Market Competitive Situation and Trends

2.8.1 Global Vebreltinib Enteric Capsules Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Vebreltinib Enteric Capsules Players Market Share by Revenue

2.8.3 Global Vebreltinib Enteric Capsules Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Vebreltinib Enteric Capsules Market Scenario by Region

3.1 Global Vebreltinib Enteric Capsules Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Vebreltinib Enteric Capsules Sales by Region: 2020-2031

3.2.1 Global Vebreltinib Enteric Capsules Sales by Region: 2020-2025

3.2.2 Global Vebreltinib Enteric Capsules Sales by Region: 2026-2031

3.3 Global Vebreltinib Enteric Capsules Revenue by Region: 2020-2031

3.3.1 Global Vebreltinib Enteric Capsules Revenue by Region: 2020-2025

3.3.2 Global Vebreltinib Enteric Capsules Revenue by Region: 2026-2031

3.4 North America Vebreltinib Enteric Capsules Market Facts & Figures by Country

3.4.1 North America Vebreltinib Enteric Capsules Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Vebreltinib Enteric Capsules Sales by Country (2020-2031)

3.4.3 North America Vebreltinib Enteric Capsules Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Vebreltinib Enteric Capsules Market Facts & Figures by Country

3.5.1 Europe Vebreltinib Enteric Capsules Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Vebreltinib Enteric Capsules Sales by Country (2020-2031)

3.5.3 Europe Vebreltinib Enteric Capsules Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Vebreltinib Enteric Capsules Market Facts & Figures by Region

3.6.1 Asia Pacific Vebreltinib Enteric Capsules Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Vebreltinib Enteric Capsules Sales by Region (2020-2031)

3.6.3 Asia Pacific Vebreltinib Enteric Capsules Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Vebreltinib Enteric Capsules Market Facts & Figures by Country

3.7.1 Latin America Vebreltinib Enteric Capsules Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Vebreltinib Enteric Capsules Sales by Country (2020-2031)

3.7.3 Latin America Vebreltinib Enteric Capsules Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Vebreltinib Enteric Capsules Market Facts & Figures by Country

3.8.1 Middle East and Africa Vebreltinib Enteric Capsules Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Vebreltinib Enteric Capsules Sales by Country (2020-2031)

3.8.3 Middle East and Africa Vebreltinib Enteric Capsules Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Vebreltinib Enteric Capsules Sales by Type (2020-2031)

4.1.1 Global Vebreltinib Enteric Capsules Sales by Type (2020-2025)

4.1.2 Global Vebreltinib Enteric Capsules Sales by Type (2026-2031)

4.1.3 Global Vebreltinib Enteric Capsules Sales Market Share by Type (2020-2031)

4.2 Global Vebreltinib Enteric Capsules Revenue by Type (2020-2031)

4.2.1 Global Vebreltinib Enteric Capsules Revenue by Type (2020-2025)

4.2.2 Global Vebreltinib Enteric Capsules Revenue by Type (2026-2031)

4.2.3 Global Vebreltinib Enteric Capsules Revenue Market Share by Type (2020-2031)

4.3 Global Vebreltinib Enteric Capsules Price by Type (2020-2031)

5 Segment by Application

5.1 Global Vebreltinib Enteric Capsules Sales by Application (2020-2031)

5.1.1 Global Vebreltinib Enteric Capsules Sales by Application (2020-2025)

5.1.2 Global Vebreltinib Enteric Capsules Sales by Application (2026-2031)

5.1.3 Global Vebreltinib Enteric Capsules Sales Market Share by Application (2020-2031)

5.2 Global Vebreltinib Enteric Capsules Revenue by Application (2020-2031)

5.2.1 Global Vebreltinib Enteric Capsules Revenue by Application (2020-2025)

5.2.2 Global Vebreltinib Enteric Capsules Revenue by Application (2026-2031)

5.2.3 Global Vebreltinib Enteric Capsules Revenue Market Share by Application (2020-2031)

5.3 Global Vebreltinib Enteric Capsules Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Avistone Pharmaceuticals Biotechnology

6.1.1 Avistone Pharmaceuticals Biotechnology Company Information

6.1.2 Avistone Pharmaceuticals Biotechnology Description and Business Overview

6.1.3 Avistone Pharmaceuticals Biotechnology Vebreltinib Enteric Capsules Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Avistone Pharmaceuticals Biotechnology Vebreltinib Enteric Capsules Product Portfolio

6.1.5 Avistone Pharmaceuticals Biotechnology Recent Developments/Updates

6.2 Asymchem

6.2.1 Asymchem Company Information

6.2.2 Asymchem Description and Business Overview

6.2.3 Asymchem Vebreltinib Enteric Capsules Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Asymchem Vebreltinib Enteric Capsules Product Portfolio

6.2.5 Asymchem Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Vebreltinib Enteric Capsules Industry Chain Analysis

7.2 Vebreltinib Enteric Capsules Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Vebreltinib Enteric Capsules Production Mode & Process Analysis

7.4 Vebreltinib Enteric Capsules Sales and Marketing

7.4.1 Vebreltinib Enteric Capsules Sales Channels

7.4.2 Vebreltinib Enteric Capsules Distributors

7.5 Vebreltinib Enteric Capsules Customer Analysis

8 Vebreltinib Enteric Capsules Market Dynamics

8.1 Vebreltinib Enteric Capsules Industry Trends

8.2 Vebreltinib Enteric Capsules Market Drivers

8.3 Vebreltinib Enteric Capsules Market Challenges

8.4 Vebreltinib Enteric Capsules Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Avistone Pharmaceuticals Biotechnology

Asymchem

List of Tables

Table 1. Global Vebreltinib Enteric Capsules Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Vebreltinib Enteric Capsules Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Vebreltinib Enteric Capsules Market Competitive Situation by Manufacturers in 2024

Table 4. Global Vebreltinib Enteric Capsules Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Vebreltinib Enteric Capsules Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Vebreltinib Enteric Capsules Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Vebreltinib Enteric Capsules Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Vebreltinib Enteric Capsules Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Vebreltinib Enteric Capsules, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Vebreltinib Enteric Capsules, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Vebreltinib Enteric Capsules, Product Type & Application

Table 12. Global Key Manufacturers of Vebreltinib Enteric Capsules, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Vebreltinib Enteric Capsules by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vebreltinib Enteric Capsules as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Vebreltinib Enteric Capsules Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Vebreltinib Enteric Capsules Sales by Region (2020-2025) & (K Units)

Table 18. Global Vebreltinib Enteric Capsules Sales Market Share by Region (2020-2025)

Table 19. Global Vebreltinib Enteric Capsules Sales by Region (2026-2031) & (K Units)

Table 20. Global Vebreltinib Enteric Capsules Sales Market Share by Region (2026-2031)

Table 21. Global Vebreltinib Enteric Capsules Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Vebreltinib Enteric Capsules Revenue Market Share by Region (2020-2025)

Table 23. Global Vebreltinib Enteric Capsules Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Vebreltinib Enteric Capsules Revenue Market Share by Region (2026-2031)

Table 25. North America Vebreltinib Enteric Capsules Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Vebreltinib Enteric Capsules Sales by Country (2020-2025) & (K Units)

Table 27. North America Vebreltinib Enteric Capsules Sales by Country (2026-2031) & (K Units)

Table 28. North America Vebreltinib Enteric Capsules Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Vebreltinib Enteric Capsules Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Vebreltinib Enteric Capsules Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Vebreltinib Enteric Capsules Sales by Country (2020-2025) & (K Units)

Table 32. Europe Vebreltinib Enteric Capsules Sales by Country (2026-2031) & (K Units)

Table 33. Europe Vebreltinib Enteric Capsules Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Vebreltinib Enteric Capsules Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Vebreltinib Enteric Capsules Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Vebreltinib Enteric Capsules Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Vebreltinib Enteric Capsules Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Vebreltinib Enteric Capsules Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Vebreltinib Enteric Capsules Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Vebreltinib Enteric Capsules Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Vebreltinib Enteric Capsules Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Vebreltinib Enteric Capsules Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Vebreltinib Enteric Capsules Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Vebreltinib Enteric Capsules Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Vebreltinib Enteric Capsules Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Vebreltinib Enteric Capsules Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Vebreltinib Enteric Capsules Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Vebreltinib Enteric Capsules Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Vebreltinib Enteric Capsules Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Vebreltinib Enteric Capsules Sales (K Units) by Type (2020-2025)

Table 51. Global Vebreltinib Enteric Capsules Sales (K Units) by Type (2026-2031)

Table 52. Global Vebreltinib Enteric Capsules Sales Market Share by Type (2020-2025)

Table 53. Global Vebreltinib Enteric Capsules Sales Market Share by Type (2026-2031)

Table 54. Global Vebreltinib Enteric Capsules Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Vebreltinib Enteric Capsules Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Vebreltinib Enteric Capsules Revenue Market Share by Type (2020-2025)

Table 57. Global Vebreltinib Enteric Capsules Revenue Market Share by Type (2026-2031)

Table 58. Global Vebreltinib Enteric Capsules Price (US$/Unit) by Type (2020-2025)

Table 59. Global Vebreltinib Enteric Capsules Price (US$/Unit) by Type (2026-2031)

Table 60. Global Vebreltinib Enteric Capsules Sales (K Units) by Application (2020-2025)

Table 61. Global Vebreltinib Enteric Capsules Sales (K Units) by Application (2026-2031)

Table 62. Global Vebreltinib Enteric Capsules Sales Market Share by Application (2020-2025)

Table 63. Global Vebreltinib Enteric Capsules Sales Market Share by Application (2026-2031)

Table 64. Global Vebreltinib Enteric Capsules Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Vebreltinib Enteric Capsules Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Vebreltinib Enteric Capsules Revenue Market Share by Application (2020-2025)

Table 67. Global Vebreltinib Enteric Capsules Revenue Market Share by Application (2026-2031)

Table 68. Global Vebreltinib Enteric Capsules Price (US$/Unit) by Application (2020-2025)

Table 69. Global Vebreltinib Enteric Capsules Price (US$/Unit) by Application (2026-2031)

Table 70. Avistone Pharmaceuticals Biotechnology Company Information

Table 71. Avistone Pharmaceuticals Biotechnology Description and Business Overview

Table 72. Avistone Pharmaceuticals Biotechnology Vebreltinib Enteric Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Avistone Pharmaceuticals Biotechnology Vebreltinib Enteric Capsules Product

Table 74. Avistone Pharmaceuticals Biotechnology Recent Developments/Updates

Table 75. Asymchem Company Information

Table 76. Asymchem Description and Business Overview

Table 77. Asymchem Vebreltinib Enteric Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Asymchem Vebreltinib Enteric Capsules Product

Table 79. Asymchem Recent Developments/Updates

Table 80. Key Raw Materials Lists

Table 81. Raw Materials Key Suppliers Lists

Table 82. Vebreltinib Enteric Capsules Distributors List

Table 83. Vebreltinib Enteric Capsules Customers List

Table 84. Vebreltinib Enteric Capsules Market Trends

Table 85. Vebreltinib Enteric Capsules Market Drivers

Table 86. Vebreltinib Enteric Capsules Market Challenges

Table 87. Vebreltinib Enteric Capsules Market Restraints

Table 88. Research Programs/Design for This Report

Table 89. Key Data Information from Secondary Sources

Table 90. Key Data Information from Primary Sources

Table 91. Authors List of This Report

List of Figures

Figure 1. Product Picture of Vebreltinib Enteric Capsules

Figure 2. Global Vebreltinib Enteric Capsules Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Vebreltinib Enteric Capsules Market Share by Type: 2024 & 2031

Figure 4. 25mg per Unit Product Picture

Figure 5. 100mg per Unit Product Picture

Figure 6. Global Vebreltinib Enteric Capsules Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Vebreltinib Enteric Capsules Market Share by Application: 2024 & 2031

Figure 8. Glioma

Figure 9. Non-small Cell Lung Cancer

Figure 10. Global Vebreltinib Enteric Capsules Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Vebreltinib Enteric Capsules Market Size (2020-2031) & (US$ Million)

Figure 12. Global Vebreltinib Enteric Capsules Sales (2020-2031) & (K Units)

Figure 13. Global Vebreltinib Enteric Capsules Average Price (US$/Unit) & (2020-2031)

Figure 14. Vebreltinib Enteric Capsules Report Years Considered

Figure 15. Vebreltinib Enteric Capsules Sales Share by Manufacturers in 2024

Figure 16. Global Vebreltinib Enteric Capsules Revenue Share by Manufacturers in 2024

Figure 17. Global 5 and 10 Largest Vebreltinib Enteric Capsules Players: Market Share by Revenue in Vebreltinib Enteric Capsules in 2024

Figure 18. Vebreltinib Enteric Capsules Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 19. Global Vebreltinib Enteric Capsules Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 20. North America Vebreltinib Enteric Capsules Sales Market Share by Country (2020-2031)

Figure 21. North America Vebreltinib Enteric Capsules Revenue Market Share by Country (2020-2031)

Figure 22. United States Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 23. Canada Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Europe Vebreltinib Enteric Capsules Sales Market Share by Country (2020-2031)

Figure 25. Europe Vebreltinib Enteric Capsules Revenue Market Share by Country (2020-2031)

Figure 26. Germany Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. France Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. U.K. Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Italy Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Russia Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Asia Pacific Vebreltinib Enteric Capsules Sales Market Share by Region (2020-2031)

Figure 32. Asia Pacific Vebreltinib Enteric Capsules Revenue Market Share by Region (2020-2031)

Figure 33. China Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Japan Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. South Korea Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. India Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Australia Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. China Taiwan Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Latin America Vebreltinib Enteric Capsules Sales Market Share by Country (2020-2031)

Figure 41. Latin America Vebreltinib Enteric Capsules Revenue Market Share by Country (2020-2031)

Figure 42. Mexico Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Brazil Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Argentina Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Colombia Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Middle East and Africa Vebreltinib Enteric Capsules Sales Market Share by Country (2020-2031)

Figure 47. Middle East and Africa Vebreltinib Enteric Capsules Revenue Market Share by Country (2020-2031)

Figure 48. Turkey Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. UAE Vebreltinib Enteric Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Global Sales Market Share of Vebreltinib Enteric Capsules by Type (2020-2031)

Figure 52. Global Revenue Market Share of Vebreltinib Enteric Capsules by Type (2020-2031)

Figure 53. Global Vebreltinib Enteric Capsules Price (US$/Unit) by Type (2020-2031)

Figure 54. Global Sales Market Share of Vebreltinib Enteric Capsules by Application (2020-2031)

Figure 55. Global Revenue Market Share of Vebreltinib Enteric Capsules by Application (2020-2031)

Figure 56. Global Vebreltinib Enteric Capsules Price (US$/Unit) by Application (2020-2031)

Figure 57. Vebreltinib Enteric Capsules Value Chain

Figure 58. Channels of Distribution (Direct Vs Distribution)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Savolitinib Tablets Market Research Report 2024

Global Ibrutinib Capsules Market Research Report 2024

Global Enteric Coated Softgels For Consumer Health Spplements Market Research Report 2024

Global Nintedanib Generics Market Research Report 2024

Global Sunitinib Generics Market Research Report 2024

Global Lenvatinib Drugs Market Research Report 2024

Anlotinib Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Regorafenib Drugs Market Research Report 2024

Global Vandetanib Tablets Market Research Report 2024

Global Selpercatinib Capsules Market Research Report 2024

Global Midostaurin Soft Capsules Market Research Report 2024

Erlotinib Hydrochloride Tablet Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Crizotinib Drugs Market Research Report 2024

Global Cabozantinib Tablets Market Research Report 2024

Global Filgotinib Tablets Market Research Report 2024

Global Axitinib Tablets Market Research Report 2024

Global Capsule Gastrointestinal Endoscopic Devices Market Research Report 2024

Global Crizotinib Capsules Market Research Report 2024

Global Enteric Empty Capsules Market Insights Forecast to 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions